Merck Unit Hit With €15.3M Competition Fine In France

Law360, Washington (December 19, 2013, 1:37 PM EST) -- France's competition authority slammed Merck & Co.'s Schering-Plough unit with a  €15.3 million fine ($20.9 million) Thursday for allegedly attempting to curb generic competition for its opioid dependence drug Subutex.

Starting in 2005, Schering-Plough, Merck and its supplier Reckitt Benckiser allegedly had an agreement to prevent an Arrow Generiques generic version of Subutex from gaining traction in the French market. The companies gave pharmacists rebates and urged sales representatives to scare pharmacists and physicians away from ordering Arrow's product once it entered the market in 2006,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.